Browsing by Author "Dane, Faysal"
Now showing items 1-9 of 9
-
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
Ozaslan, Ersin; Karaca, Halit; Koca, Sinan; Sevinc, Alper; Hacioglu, Bekir; Ozkan, Metin; Ozcelik, Melike; Duran, Ayse O.; Hacibekiroglu, Ilhan; Yildiz, Yasar; Tanriverdi, Ozgur; Menekse, Serkan; Aksoy, Asude; Bozkurt, Oktay; Urvay, Semiha; Uysal, Mukremin; Demir, Hacer; Ciltas, Aydin; Dane, Faysal (LIPPINCOTT WILLIAMS & WILKINS, 2017)The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were ... -
EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.
Gumus, Mahmut; Geredeli, Caglayan; Ucar, Mahmut; Kaya, Serap; Demir, Hacer; Unal, Olcun Umit; Degirmenci, Mustafa; Dogu, Gamze Gokoz; Turan, Nedim; Yildirim, Nilgun; Basal, Fatma Bugdayci; Arpaci, Erkan; Karaagac, Mustafa; Harputluoglu, Hakan; Turk, Had Mehmet; Dane, Faysal; Ozkan, Metin (AMER SOC CLINICAL ONCOLOGY, 2017)… -
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma
Turan, Nedim; Benekli, Mustafa; Unal, Olcun Umit; Unek, Ilkay Tugba; Tastekin, Didem; Dane, Faysal; Algin, Efnan; Ulger, Sukran; Eren, Tulay; Topcu, Turkan Ozturk; Turkmen, Esma; Babacan, Nalan Akgul; Tufan, Gulnihal; Urakci, Zuhat; Ustaalioglu, Basak Oven; Uysal, Ozlem Sonmez; Ercelep, Ozlem Balvan; Taskoylu, Burcu Yapar; Aksoy, Asude; Canhoroz, Mustafa; Demirci, Umut; Dogan, Erkan; Berk, Veli; Balakan, Ozan; Ekinci, Ahmet Siyar; Uysal, Mukremin; Petekkaya, Ibrahim; Ozturk, Selcuk Cemil; Tonyali, Onder; Cetin, Bulent; Aldemir, Mehmet Naci; Helvaci, Kaan; Ozdemir, Nuriye; Oztop, Ilhan; Coskun, Ugur; Uner, Aytug; Ozet, Ahmet; Buyukberber, Suleyman (AME PUBL CO, 2015)Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed ... -
Multicenter experience of adult medulloblastoma: A study of Anatolian Society of Medical Oncology (ASMO)
Esbah, Onur; Demirci, Umut; Dane, Faysal; Gunaydsin, Yusuf; Ozdemir, Nuriye; Ekinci, Ahmet Siyar; Kodaz, Hilmi; Yazilitas, Dogan; Rzayev, Rashad; Guney, Yildiz; Seker, Metin; Uysal, Mukremin; Inal, Ali; Bilici, Ahmet; Benekli, Mustafa; Oksuzoglu, Berna; Buyukberber, Suleyman (ZERBINIS MEDICAL PUBL, 2016)Purpose: Medulloblastoma (MB) is rarely seen in adults. For adjuvant therapy in adults the same therapy protocols used in pediatric cases are used. The present study retrospectively evaluated the data of MB patients who ... -
The prognostic value of lymph node ratio in patients with curatively resected pancreatic adenocarcinoma.
Turan, Nedim; Araz, Murat; Algin, Efnan; Unal, Olcun Umit; Benekli, Mustafa; Tastekin, Didem; Dane, Faysal; Unek, Tugba; Eren, Tulay; Turkmen, Esma; Kacan, Turgut; Aldemir, Mehmet Naci; Ekinci, Ahmet Siyar; Ulger, Sukran; Urakci, Zuhat; Aksoy, Asude; Tufan, Gulnihal; Coskun, Ugur; Ozet, Ahmet; Buyukberber, Suleyman (AMER SOC CLINICAL ONCOLOGY, 2015)… -
Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers
Cihan, Sener; Kucukoner, Mehmet; Ozdemir, Nuriye; Dane, Faysal; Sendur, Mehmet Ali Nahit; Yazilitas, Dogan; Urakci, Zuhat; Durnali, Ayse; Yuksel, Sinemis; Aksoy, Sercan; Colak, Dilsen; Seker, Mehmet Metin; Taskoylu, Burcu Yapar; Oguz, Arzu; Isikdogan, Abdurrahman; Zengin, Nurullah (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: The standard therapy for stage I rectum cancer is surgical resection. Currently, there is no strong evidence to suggest that any type of adjuvant therapy is beneficial. The risks of local relapse and distant ... -
Retrospective analysis of 178 patients with stage I rectum cancer.
Cihan, Sener; Ozdemir, Nuriye; Urakci, Zuhat; Kucukoner, Mehmet; Dane, Faysal; Yazilitas, Dogan; Durnali, Ayse; Yuksel, Sinemis; Colak, Dilsen; Seker, Metin; Taskoylu, Burcu; Aksahin, Arzu; Ozturk, Banu; Demirci, Umut; Turan, Nedim; Aksoy, Sercan; Atasoy, Ajlan (AMER SOC CLINICAL ONCOLOGY, 2013)… -
What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study.
Kaplan, Muhammet Ali; Urakci, Zuhat; Gumus, Mahmut; Arslan, Ulku Yalcintas; Geredeli, Caglayan; Ozdemir, Nuriye; Koca, Dogan; Oruc, Zeynep; Uysal, Mukremin; Dane, Faysal; Sevinc, Alper; Seker, Mehmet Metin; Aksoy, Asude; Kucukoner, Mehmet; Pilanci, Kezban Nur; Topcu, Turkan Ozturk; Karaagac, Mustafa; Yildiz, Ramazan; Isikdogan, Abdurrahman (AMER SOC CLINICAL ONCOLOGY, 2015)… -
XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
Duran, Ayse Ocak; Karaca, Halit; Besiroglu, Mehmet; Bayoglu, Ibrahim Vedat; Menekse, Serkan; Yapici, Heves Surmeli; Yazilitas, Dogan; Bahceci, Aykut; Uysal, Mukremin; Sevinc, Alper; Hacibekiroglu, Ilhan; Aksoy, Asude; Tanriverdi, Ozgur; Arpaci, Erkan; Inanc, Mevlude; Dane, Faysal; Ozkan, Metin (ASIAN PACIFIC ORGANIZATION CANCER PREVENTION, 2014)Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare ...